ATMP manufacturers don’t just fight the biology — they fight the procurement process. Supply bottlenecks for GMP-grade sera, missing documentation packages, 8-week lead times from US suppliers: these are the delays that push clinical timelines back by months. This article covers which materials matter at each process step — and how to source them from EU stock without minimum order constraints.
The three most common bottlenecks in ATMP production
Lead time
Suppliers outside the EU: 6–12 weeks from order to delivery. Clinical production windows are not built for that.
Documentation
CoA, USP Class VI, BSE/TSE declaration, gamma sterilisation certificate — available on request, not as standard. Slows supplier qualification significantly.
Minimum orders
Pallet minimums for sera and single-use bags. Economically unworkable for small clinical batches.
Materials by process step — what actually matters
ATMP manufacturing involves different process steps depending on the modality. Here are the most relevant — with the materials that determine success or rework in practice.
Cell expansion is the most critical step: lot-to-lot variability in serum translates directly into cell viability, yield and ultimately therapy outcome. CAR-T production, iPSC differentiation and MSC expansion each have different requirements — but all share the need for a defined, documented starting serum.
What gets used:
- Human Serum (GMP Grade) — for xeno-free expansion protocols; preferred for human ATMPs; Type AB or pooled OTC depending on the protocol
- FBS Low Endotoxin — where FBS is still in the protocol; endotoxin control is critical for sensitive cell lines
- BSA / HSA — as medium supplement in serum-free formulations; BSA Fatty Acid-Free for lipid-sensitive cells
- Serum-Free Media — increasingly standard; HEK293 Medium GMP Grade for hybridoma and viral vector production
AAV and lentiviral vectors are produced in HEK293 or Sf9 cells. The production platform dictates media requirements. HEK293-based production — the standard for AAV in clinical development — requires a defined, serum-free medium with stable GMP documentation, particularly when the material feeds into IND or IMPD dossiers.
- Serum-Free HEK293 Medium GMP Grade — directly applicable for AAV and lentivirus production; supplied with full GMP documentation package
- 2D Bioprocessing Bags — for media hold and small production volumes up to 50 L; ISO Class 7 cleanroom, gamma-sterilised
- 3D Bioprocessing Bags — for scale-up of vector production 50–3,000 L; same certification basis as 2D
Downstream steps — chromatography, TFF, formulation — require large volumes of buffered solutions and defined excipients. Single-use bags replace stainless steel tanks without cleaning validation between batches. HSA and rHSA are used as stabilisers in final drug product formulation.
- 3D Bioprocessing Bags (100–3,000 L) — buffer hold between chromatography steps; no CIP required
- HSA / rHSA — stabiliser in final formulation of cell therapy products and viral vectors
- BSA Low Endotoxin — for buffer formulations where BSA is used as a carrier protein
ATMP release under Annex 1 and EMA ATMP guidelines requires complete material documentation. Every component in the process must be traceable — from raw material to final product. Missing supplier documentation is the most common cause of delays in regulatory review.
- Certificate of Analysis (CoA) — lot-specific for every material
- USP <87> / <88> Class VI certificate (bags and contact materials)
- Gamma sterilisation certificate ISO 11137 (SAL 10⁻⁶)
- BSE/TSE-free declaration (sera and animal-derived products)
- ISO Class 7 cleanroom declaration (single-use bags)
- BPOG-aligned extractables data (on request)
Documentation package — what comes standard
This is what SeamlessBio includes with every delivery as standard — no surcharge, no request form required:
| Document | Sera & Albumin | Single-Use Bags | Media |
|---|---|---|---|
| Certificate of Analysis (CoA) | ✓ Lot-specific | ✓ Lot-specific | ✓ Lot-specific |
| USP <87> / <88> Class VI | ✓ | ✓ | on request |
| ISO 10993 compliance | ✓ | ✓ | — |
| BSE/TSE-free declaration | ✓ | — | ✓ (animal-derived components) |
| Gamma sterilisation certificate | — | ✓ ISO 11137 | — |
| ISO Class 7 cleanroom declaration | — | ✓ | — |
| MSDS / SDS | ✓ | ✓ | ✓ |
| BPOG extractables data | — | on request | — |
Who calls us — and why
ATMP CDMOs
Contract manufacturers running parallel client programmes need lot-specific documentation for each, often with client-specific labelling. A EU supplier without minimum order requirements makes it possible to supply three different CAR-T programmes in the same week — each with its own CoA and its own shipping paperwork.
Academic ATMP facilities
University hospitals and research centres manufacturing ATMPs for Phase I clinical trials work in very small volumes. A pallet minimum order for GMP human serum is economically unworkable. SeamlessBio delivers single bottles with a full GMP documentation package — for clinical use, not for screening.
Pharma companies scaling up ATMP
When a pharma company moves from Phase II pilot (100–200 L) to Phase III commercial scale (1,000–3,000 L), it needs the same supplier across both scales — with the same documentation package. SeamlessBio supplies single-use bags from 50 mL to 3,000 L under one roof.
Frequently asked questions
Which serum is suitable for CAR-T cell expansion — Human Serum or FBS?
It depends on the protocol. For human ATMP applications — anything that ultimately goes into a patient — Human Serum (Type AB or pooled OTC) is increasingly used, as it better meets xeno-free requirements and EMA guidelines for ATMPs. FBS Low Endotoxin with batch reservation is the alternative where the protocol is still FBS-based. SeamlessBio supplies both with full GMP documentation from EU stock.
Which single-use bags are suitable for AAV vector production?
2D bags (50 mL–50 L) for small volumes and 3D bags (50–500 L) for scale-up. Both use RENOLIT 9101 multilayer film, are USP Class VI certified and gamma-sterilised (ISO 11137, SAL 10⁻⁶). The documentation package is suitable for IND/IMPD submissions.
How quickly can SeamlessBio deliver for unplanned production windows?
Standard delivery from EU stock: 2–4 business days to Germany and Austria; 3–5 business days to Switzerland. Express delivery available on request. Contact us with your volume and required delivery date — we confirm availability the same day.
Is batch reservation possible for clinical studies?
Yes. For clinical programmes with fixed production plans, we reserve lots for 6–24 months — with binding price stability and guaranteed availability. Batch reservation documentation is suitable for regulatory dossiers. Contact us for a batch reservation quote.
What documentation is needed for EMA ATMP submissions?
For ATMP dossiers under EMA Regulation (EC) No 1394/2007, typical requirements include: lot-specific CoA, USP Class VI certification, gamma sterilisation certificate, BSE/TSE-free declaration, and extractables data. SeamlessBio provides all of these as standard with every delivery — no surcharge, no request form.
Materials for your ATMP programme — from EU stock
Tell us your process steps: cell expansion, viral vector production or downstream. We recommend the right material package including documentation — within 24 hours.
Get in touch Visit the shop
English
Deutsch